The Alternative NFkB Pathway in Survival and Function of Anti-Viral T Cells
抗病毒 T 细胞存活和功能中的替代 NFkB 途径
基本信息
- 批准号:7487426
- 负责人:
- 金额:$ 18.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-01 至 2009-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdjuvantAnimalsAntigensApoptoticCell Differentiation processCell SurvivalCellsCytokine ReceptorsEffector CellFamilyGenerationsImmune responseInfectionInflammatoryLifeLymphocyteLymphocytic choriomeningitis virusLymphoidMammalsMemoryMusOrganPathway interactionsProliferatingProteinsSignal PathwaySignal TransductionSystemT memory cellT-LymphocyteTestingTransgenesTumor Necrosis Factor ReceptorViralVirus DiseasesWorkcytokinedifferentiated B cellflymemberresearch studyresponseretroviral transduction
项目摘要
Description (provided by applicant): The NFkB system is an ancient intracellular signaling pathway that coordinates the inflammatory immune response to infection in animals as diverse as worms, flies, and mammals. In lymphocytes, signals from antigen and cytokine receptors cause acute and transient activation of NFkB through the canonical pathway by triggering IkB degradation. Stimulation via a select set of cytokine receptors, including some members of the TNFR family, causes sustained activation of NFkB through the IkB-independent, NIK-dependent alternative pathway. This alternative NFkB activation pathway has recently been shown to govern formation of secondary lymphoid organs and determine the fate of newly differentiated B cells, but its function in T cells is unknown. The working hypothesis of this proposal is that sustained activation of the alternative NFkB pathway in proliferating T cells in response to late costimulatory signals induces and maintains expression of the cytokines, cytokine receptors, and anti-apoptotic proteins that are necessary for responding T cells to function as differentiated effector cells and survive as memory cells. We will test this hypothesis using mice with T cells that are deficient in the alternative NFkB pathway to determine whether the alternative pathway is necessary for T cell differentiation to effector cells and survival as long-lived memory cells in the immune response to lymphocytic choriomeningitis virus. Using retroviral transduction and Cre-inducible transgenes to express active components of the alternative pathway in T cells, we will determine whether activation of the alternative pathway is sufficient to enable generation of effector and memory T cells when costimulatory signals are limiting. The experiments proposed in this application may demonstrate that the alternative NFkB pathway is a necessary common feature of the diverse costimulatory signals that enable responding T cells to become effector cells and long-lived memory cells. An effective immune response to virus infection requires late costimulatory signals provided by the innate immune response or by adjuvants to enable the responding T cells to differentiate to effector cells and survive as long-lived memory cells. The experiments proposed in this application may demonstrate that the alternative NFkB pathway is a necessary common feature of the diverse costimulatory signals that enable responding T cells to become effector cells and long-lived memory cells.
描述(由申请人提供):NFkB系统是一种古老的细胞内信号通路,协调蠕虫、苍蝇和哺乳动物等多种动物对感染的炎症免疫反应。在淋巴细胞中,来自抗原和细胞因子受体的信号通过引发IkB降解的典型途径引起NFkB的急性和短暂激活。通过一系列细胞因子受体(包括TNFR家族的一些成员)的刺激,通过ikb独立、nik依赖的替代途径导致NFkB的持续激活。这种可选择的NFkB激活途径最近被证明控制次级淋巴器官的形成并决定新分化B细胞的命运,但其在T细胞中的功能尚不清楚。该建议的工作假设是,在增殖的T细胞中,为了响应晚期共刺激信号,NFkB通路的持续激活可诱导并维持细胞因子、细胞因子受体和抗凋亡蛋白的表达,这些是应答T细胞作为分化效应细胞和作为记忆细胞存活所必需的。我们将使用缺乏NFkB替代通路的T细胞小鼠来验证这一假设,以确定在淋巴细胞性脉络丛脑膜炎病毒的免疫反应中,替代通路是否对T细胞分化为效应细胞和作为长期记忆细胞存活是必要的。利用逆转录病毒转导和可诱导基因在T细胞中表达可选通路的活性成分,我们将确定当共刺激信号受限时,可选通路的激活是否足以使效应T细胞和记忆T细胞产生。本应用中提出的实验可能表明,NFkB通路是多种共刺激信号的必要共同特征,这些信号使应答T细胞成为效应细胞和长寿命记忆细胞。对病毒感染的有效免疫应答需要先天免疫应答或佐剂提供的晚期共刺激信号,以使应答的T细胞分化为效应细胞并作为长寿命记忆细胞存活。本应用中提出的实验可能表明,NFkB通路是多种共刺激信号的必要共同特征,这些信号使应答T细胞成为效应细胞和长寿命记忆细胞。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Cell-intrinsic role for NF-kappa B-inducing kinase in peripheral maintenance but not thymic development of Foxp3+ regulatory T cells in mice.
- DOI:10.1371/journal.pone.0076216
- 发表时间:2013
- 期刊:
- 影响因子:3.7
- 作者:Murray SE
- 通讯作者:Murray SE
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID C PARKER其他文献
DAVID C PARKER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID C PARKER', 18)}}的其他基金
The non-canonical NF-kappaB pathway in survival and function of T lymphocytes
T 淋巴细胞存活和功能中的非经典 NF-kappaB 通路
- 批准号:
8261672 - 财政年份:2011
- 资助金额:
$ 18.88万 - 项目类别:
The non-canonical NF-kappaB pathway in survival and function of T lymphocytes
T 淋巴细胞存活和功能中的非经典 NF-kappaB 通路
- 批准号:
8460461 - 财政年份:2011
- 资助金额:
$ 18.88万 - 项目类别:
The non-canonical NF-kappaB pathway in survival and function of T lymphocytes
T 淋巴细胞存活和功能中的非经典 NF-kappaB 通路
- 批准号:
8186294 - 财政年份:2011
- 资助金额:
$ 18.88万 - 项目类别:
The non-canonical NF-kappaB pathway in survival and function of T lymphocytes
T 淋巴细胞存活和功能中的非经典 NF-kappaB 通路
- 批准号:
8653526 - 财政年份:2011
- 资助金额:
$ 18.88万 - 项目类别:
B Cell Subsets as Antigen-presenting Cells in Peripheral Self-tolerance
B 细胞亚群作为外周自我耐受中的抗原呈递细胞
- 批准号:
7364592 - 财政年份:2007
- 资助金额:
$ 18.88万 - 项目类别:
B Cell Subsets as Antigen-presenting Cells in Peripheral Self-tolerance
B 细胞亚群作为外周自我耐受中的抗原呈递细胞
- 批准号:
7266093 - 财政年份:2007
- 资助金额:
$ 18.88万 - 项目类别:
The Alternative NFkB Pathway in Survival and Function of Anti-Viral T Cells
抗病毒 T 细胞存活和功能中的替代 NFkB 途径
- 批准号:
7391936 - 财政年份:2007
- 资助金额:
$ 18.88万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 18.88万 - 项目类别: